Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 9/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22766689 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL17027260 | 0.79 | KDM4E (0.35) | KDM4EALDH1A1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL3601425 | 0.72 | PDK2 (0.38) | KDM4EALDH1A1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL1450379 | 0.71 | BRD4 (0.51) | KDM4EALDH1A1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL3595402 | 0.68 | BRD4 (0.37) | KDM4EALDH1A1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL3642063 | 0.68 | PARP1 (0.56) | SMN1; SMN2BRD4PDE3BPDE3A | |
| SCHEMBL3589207 | 0.68 | PARP1 (0.56) | SMN1; SMN2BRD4PDE3BPDE3A | |
| SCHEMBL3637630 | 0.68 | PARP1 (0.56) | SMN1; SMN2BRD4PDE3BPDE3A | |
| SCHEMBL3599771 | 0.67 | NR3C2 (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3593391 | 0.66 | RXFP1 (0.36) | KDM4EALDH1A1BRD4PDK2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | KDM4E 2284/4885ALDH1A1 1904/4885SMN1; SMN2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.